This is the first cost-effectiveness model comparing COPAXONE ® and Tysabri ® for treatment of multiple sclerosis (MS) to take into consideration long-term treatment outcomes, where available, effects ...
A generic version of multiple sclerosis drug Copaxone was introduced in 2015, but it has done little to lower drug costs for MS patients, NPR reported. Yearly costs for MS drugs can run as high as $50 ...
Sometimes, the approval of a new generic drug offers more hype than hope for patients' wallets, as people with multiple sclerosis know all too well. New research shows just how little the introduction ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results